Search the Newsreel

Earnings Preview: Clarivate to Report Financial Results Pre-market on July 29

Clarivate Plc (NYSE: CLVT) is scheduled to report its financial results before the market opens on July 29, 2026. Analysts currently project the company will announce a quarterly loss of $0.01 per share and revenue of $426.65 million. Investors will be closely watching these …

Monashee Investment Management LLC Invests $1.88 Million in Aclaris Therapeutics, Inc. $ACRS

Clarivate (CLVT) Projected to Announce Earnings on Wednesday

Clarivate (CLVT) is expected to announce its Q2 2026 earnings on Wednesday, July 29th, with analysts projecting $0.17 EPS and $589.7 million in revenue. The company beat expectations in its last quarter, reporting $0.18 EPS, and currently holds a consensus "Reduce" rating from analysts …

Sodexo selected by Clariant to deliver global integrated workplace services

Sodexo SA Sodexo announces today a new five-year global partnership with Clariant, one of the world's leading speciality chemical companies. The agreement includes a wide range of soft and hard FM services from cleaning, to building, grounds maintenance and technical support. The scope covers …

Clarivate's trademark AI draws on 172.5M records in 188 jurisdictions

Clarivate's AI-powered trademark risk assessment solution, RiskMark, has received the 2026 CODiE Award for Best AI Tool for Lawyers. Launched in 2025, RiskMark leverages 172.5 million trademark records and over five million decisions to assist legal professionals in evaluating trademark confusion and risk efficiently. …

Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 52-Week High - Here's Why

Clarivate (NYSE:CLVT) Shares Down 5.2% - Here's Why

Clarivate (NYSE:CLVT) shares dropped 5.2% on Monday, trading below their previous close with significantly reduced volume. Despite beating quarterly EPS and revenue estimates, the company's revenue declined year-over-year, and analyst ratings are mixed, with a consensus of "Reduce" and a price target of $2.98. …

Clarivate's RiskMark Wins 2026 CODiE Award for Best AI Tool for Lawyers

Clarivate's RiskMark has won the 2026 CODiE Award for Best AI Tool for Lawyers, recognized for its innovative use of predictive and generative AI in the legal industry. The tool, built on extensive trademark and legal records, significantly enhances efficiency and accuracy for legal …

Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11

Piper Sandler has reiterated its Buy rating on Aclaris Therapeutics (ACRS.US) while maintaining a target price of $11. This indicates continued confidence in the company's prospects from the investment firm.

Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)

Piper Sandler analyst Biren Amin has reiterated a Buy rating on Aclaris Therapeutics (ACRS) with an $11.00 price target. This comes despite negative insider sentiment, indicated by recent share sales, and the company reporting a GAAP net loss of $19.82 million in its latest …

Clarivate (CLVT) Could Be 43% Undervalued After France Library Win

Clarivate (CLVT) has secured a significant contract with France’s Bibliographic Agency for Higher Education, Abes, to modernize its national academic library system. Despite recent short-term stock momentum, the company's shares have seen a decline over the past year, leading to a narrative that the …

CMNN5201543 Bond Risk Profile

This page provides an overview of the CMNN5201543 bond issued by Clarivate Plc, specifically its 4.875% bond maturing on June 30, 2029. It outlines key metrics for risk assessment, including credit risk and issuer rating, to help users evaluate the bond's reliability and make …

USPTO Launches AI Image Search in Trademark Search System, Powered by Clarivate

The U.S. Patent and Trademark Office (USPTO) has launched an AI-assisted image search feature within its public trademark search system, TM Search, powered by Clarivate Plc. This new capability enables users to upload images and compare them against the U.S. trademark register to identify …

Clarivate selected by Singapore's National Library Board for automation solutions

Clarivate Plc has been chosen by Singapore's National Library Board (NLB) to provide library software solutions from its Innovative division. The solutions, including Polaris Integrated Library System and Vega Discover applications, will support NLB's Libraries and Archives Blueprint 2025 (LAB25) and aim to enhance …

Clarivate Supports USPTO with AI Image Search Launch

Clarivate has partnered with the USPTO to introduce an AI-assisted image search feature that significantly enhances trademark search efficiency and quality. This technology uses advanced image recognition to help users identify visually similar trademarks, addressing a critical challenge in traditional search methods. The collaboration …

USPTO Lets Users Upload Images to Search U.S. Trademarks

Clarivate (NYSE: CLVT) has partnered with the U.S. Patent and Trademark Office (USPTO) to launch an AI-assisted image search capability within the TM Search system. This new feature allows users to upload images and compare them against the U.S. trademark register to identify visually …

Claritev’s Second-Quarter Results Arrive Before Markets Open

Is Clarivate (CLVT) Quietly Repositioning as Core Infrastructure for AI-Powered Academic Research Systems?

Clarivate (CLVT) recently secured a multi-year agreement with France’s Bibliographic Agency for Higher Education (Abes) to modernize the national academic library infrastructure using its cloud platform, indicating a potential repositioning as core infrastructure for AI-powered academic research. This deal strengthens Clarivate's investment narrative focused …

ASX Stocks Recording Encouraging Gains Today: Why Investors Are Watching Clarity Pharmaceuticals, Vault Minerals, Astron and Boss Energy

Clarity Pharmaceuticals (ASX:CU6) Rallies Nearly 15%: Is This ASX Healthcare Stock Worth Watching?

Clarity Pharmaceuticals (ASX:CU6) Gains as Radiopharma Stocks Stay Hot

Aclaris Therapeutics (ACRS) Declines 1.6% as Shares Approach Support at $4.67 - Ease of Movement

Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS

Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS)

ACRS Forecast — Price Target — Prediction for 2027

Clarity Pharmaceuticals Shares Close At 52-Week Low: The Latest

ACRS Q1 2026 Earnings: Slimmer Loss Beats Estimates as Stock Rebounds - Full Year Guidance

Clarity Pharmaceuticals (ASX:CU6): Biotech Stock Falls as Investors Watch Trial Progress

Clarity Pharmaceuticals (ASX:CU6) Plunges as Clinical-Stage Biotech Sell-Off Continues

Clarity Pharmaceuticals (CU6 ASX: CU6) Rises 9% as Traders Rotate Into Biotech Stocks

Claritev (CTEV) Q1 2026 Loss Of US$4.41 Per Share Tests Bullish Margin Narratives

Earnings call transcript: Claritev’s Q1 2026 shows strong revenue growth

Claritev Corporation (CTEV) Reports Q1 Loss, Tops Revenue Estimates

Trade Alert: CEO, MD & Executive Director Of Clarity Pharmaceuticals Michelle Parker Has Sold Stock

Clarity Pharmaceuticals (ASX:CU6) Analysis: Sector Weakness and Governance Changes Weigh on Sentiment

Why Is Clarity Pharmaceuticals (ASX:CU6) Stock Surging Today?